These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27628534)

  • 21. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.
    Kushimoto S; Fukuoka T; Kimura A; Toyoda K; Brainsky A; Harman A; Chung T; Yasaka M
    Int J Hematol; 2017 Dec; 106(6):777-786. PubMed ID: 28815410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies.
    Milling TJ; Refaai MA; Goldstein JN; Schneider A; Omert L; Harman A; Lee ML; Sarode R
    Ann Emerg Med; 2016 Jan; 67(1):96-105.e5. PubMed ID: 26094105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergent reversal of vitamin K antagonists: addressing all the factors.
    Martin DT; Barton CA; Dodgion C; Schreiber M
    Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
    Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
    J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials.
    Milling TJ; Refaai MA; Sarode R; Lewis B; Mangione A; Durn BL; Harman A; Lee ML; Goldstein JN
    Acad Emerg Med; 2016 Apr; 23(4):466-75. PubMed ID: 26822172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
    Puchstein D; Kork F; Schöchl H; Rayatdoost F; Grottke O
    Thromb Haemost; 2023 Jan; 123(1):40-53. PubMed ID: 36626899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-label use of 4-factor prothrombin complex concentrate is common despite little known benefit: A retrospective study.
    Scharman CD; Shatzel JJ; Kim E; DeLoughery TG
    Eur J Haematol; 2018 Sep; 101(3):349-353. PubMed ID: 29862565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation.
    Sun GH; Patel V; Moreno-Duarte I; Zahedi F; Ursprung E; Couper G; Chen FY; Welsby IJ; Comenzo R; Kao G; Cobey FC
    J Cardiothorac Vasc Anesth; 2018 Feb; 32(1):161-167. PubMed ID: 29198634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
    Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On-label compared to off-label four-factor prothrombin complex concentrate use: a retrospective, observational study.
    Cho BC; Jung YH; DeMario VM; Lau E; Podlasek SJ; Grant MC; Gehrie EA; Frank SM
    Transfusion; 2019 Aug; 59(8):2678-2684. PubMed ID: 31121073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use.
    Uttaro E; Young MR; Falvey J; Corvelli JM; Acquisto NM
    Transfus Apher Sci; 2023 Oct; 62(5):103759. PubMed ID: 37453907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
    Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
    J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
    Santibanez M; Lesch CA; Lin L; Berger K
    J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization and safety of off-label prothrombin complex concentrate (4F-PCC) in a nonsurgical population.
    Sandquist K; Kaucher K; Newell J; Sarangarm P; Burnett A
    Blood Coagul Fibrinolysis; 2024 Jun; 35(4):161-166. PubMed ID: 38477829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.
    Refaai MA; Goldstein JN; Lee ML; Durn BL; Milling TJ; Sarode R
    Transfusion; 2015 Nov; 55(11):2722-9. PubMed ID: 26135740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting.
    Joseph R; Burner J; Yates S; Strickland A; Tharpe W; Sarode R
    Transfusion; 2016 Apr; 56(4):799-807. PubMed ID: 26589481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.